Search results
Results from the WOW.Com Content Network
Antipsychotics by class Generic name Brand names Chemical class ATC code Typical antipsychotics; Acepromazine: Atravet, Acezine: phenothiazine: N05AA04
First-generation antipsychotics have a longer history of use, efficacy and safety in pregnancy, particularly chlorpromazine and haloperidol. [32] Still, second-generation antipsychotics may be preferred over first-generation antipsychotics due to the reduced risk for extrapyramidal symptoms (e.g., uncontrollable movements, tremors or muscle ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication. The list is not exhaustive and not all drugs are used regularly in all countries.
List of investigational antipsychotics; List of investigational anxiolytics; List of investigational attention deficit hyperactivity disorder drugs; List of investigational autism and pervasive developmental disorder drugs; List of investigational hallucinogens and entactogens; List of investigational obsessive–compulsive disorder drugs
Use in pregnancy and breastfeeding is generally not recommended. [10] It is a typical antipsychotic which is believed to work by reducing the action of dopamine in the brain. [6] Prochlorperazine was approved for medical use in the United States in 1956. [6] It is available as a generic medication. [7]
National Institute for Health and Care Excellence#Clinical guidelines To a section : This is a redirect from a topic that does not have its own page to a section of a page on the subject. For redirects to embedded anchors on a page, use {{ R to anchor }} instead .
Use during pregnancy is of unclear safety. [13] [14] Lurasidone was first approved for medical use in the United States in 2010. [2] In 2013, it was approved in Canada and by the U.S. Food and Drug Administration (FDA) to treat bipolar depression, either as monotherapy or adjunctively with lithium or valproate.